Back to search results

Beta-glucan for Non-Small Cell Lung Cancer

This study is looking at how a dietary supplement called beta-glucan affects the immune system in people with non-small cell lung cancer (NSCLC). Beta-glucan is an over-the-counter supplement made from baker's yeast that may help your body's immune cells fight cancer. Researchers will take blood samples before and after treatment with beta-glucan to see if it makes certain immune cells (neutrophils) more active. If you have suspected or confirmed NSCLC, are at least 18 years old, and haven't had recent cancer treatment, you might be able to join. The study aims to enroll 300 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 300 participants. The phase of the study is not specified.
What's involved
You would have blood drawn before and after treatment with beta-glucan. If you have surgery, resected lung tissue will be tested after the surgery.
Compensation
Not stated in the trial record.
Follow-up
Blood specimens will be taken pre-treatment and post-treatment. Resected lung tissue will be tested post-treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00682032

The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Recruiting
NAAges 18+InterventionalBasic science
University of Louisville
~300 participants
Updated 2025-01-10 on ClinicalTrials.gov
What's tested:beta-glucan

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
blood specimens will be obtained to examine the ability of beta-glucan to prime neutrophils complement receptor 3 (CR3) and test the cytotoxicity of the primed neutrophils.
Measured over pre-treatment and post-treatment
+1 more outcome measured

Conditions

Non Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Kentucky1

Study leadership

  • Goetz H Kloecker, MD · PRINCIPAL_INVESTIGATOR · James Graham Brown Cancer Center

Who to contact

Clinical Trials Office, Brown Cancer Center
[email protected]
(502) 562-3429
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)
treatment naive or no treatment within 6 months prior to enrollment
able to swallow pills
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
absolute neutrophil count (ANC) at least 1500/microl
able to understand and willing to sign a written informed consent document
resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon
treatment naive
able to swallow pills
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
must be an operative candidate
absolute neutrophil count (ANC) at least 1500/microl
able to understand and willing to sign a written informed consent document

Exclusion

history of hypersensitivity reactions attributed to beta-glucan
currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
history of hypersensitivity reactions attributed to beta-glucan
currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

What this trial measures

  • blood specimens will be obtained to examine the ability of beta-glucan to prime neutrophils complement receptor 3 (CR3) and test the cytotoxicity of the primed neutrophils.pre-treatment and post-treatment

    compare CR3 CBRM1/5 expression, CR3-dependent cellular cytotoxicity, myeloid-derived suppressor cells (MDSC) frequency, and T-cell function (cytokine secretion) before and after beta-glucan uptake

  • resected lung tissue will be tested to determine macrophage phenotypepost-treatment

    AIM 3 only